CompletedPhase 2NCT05626634
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Studying Infantile epileptic-dyskinetic encephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Longboard Pharmaceuticals
- Principal Investigator
- Dennis J Dlugos, MDChildren's Hospital of Philadelphia
- Intervention
- LP352, bexicaserin(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 12-65 years · All sexes
- Timeline
- 2022 – 2024
Study locations (28)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Rancho Los Amigos National Rehabilitation Center (RLANRC), Downey, California, United States
- University of California San Francisco, San Francisco, California, United States
- Northwest Florida Clinical Research Group, Gulf Breeze, Florida, United States
- University of Miami, Miami, Florida, United States
- Advent Health Orlando, Orlando, Florida, United States
- Research Institute of Orlando, Orlando, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
- Spectrum Health, Grand Rapids, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Boston Children's Health Physicians LLP, Hawthorne, New York, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05626634 on ClinicalTrials.govOther trials for Infantile epileptic-dyskinetic encephalopathy
Additional recruiting or active studies for the same condition.
See all trials for Infantile epileptic-dyskinetic encephalopathy →